Fanconi anemia group A protein (FANCA) (FANCA)

Fanconi anemia group A protein (FANCA) is a critical component of the Fanconi anemia (FA) core complex, which functions as an E3 ubiquitin ligase essential for the repair of DNA interstrand cross-links [1, 4, 6]. It facilitates the monoubiquitination of the FANCD2-FANCI complex, thereby activating the downstream FA-BRCA pathway for homologous recombination and DNA repair [4, 13, 16]. Mutations in the FANCA gene are the primary cause of Fanconi anemia, an autosomal recessive disorder characterized by progressive bone marrow failure, developmental anomalies, and a significantly elevated risk of malignancies such as acute myeloid leukemia and squamous cell carcinomas [2, 6, 8, 17]. In the context of oncology, somatic or germline loss of FANCA function induces a state of genomic instability similar to BRCA deficiency, making these tumors susceptible to platinum-based chemotherapies and PARP inhibitors via synthetic lethality [14, 15]. Therapeutic development for FANCA-related disorders primarily involves ex vivo lentiviral gene therapy (e.g., RP-L102) to restore functional protein expression in hematopoietic stem cells [7, 11, 12]. Additionally, FANCA status serves as a vital biomarker for diagnosing FA through chromosomal breakage assays and for stratifying cancer patients for DNA-targeted therapies [1, 14, 16].

Other names

FA1 [1]FAA [1]FACA [1]FA [1]FA-H [1]FAH [1]FANCH [1, 4]

Lentiviral-mediated gene replacement [7, 11, 12]; Synthetic lethality via PARP inhibition [14, 15]; DNA interstrand cross-link induction [1, 6, 13]